Lixisenatide
Unchecked
This page is only a stub and has not yet been reviewed. Any and all facts within are questionable. Please feel free to fill in gaps where you know how to fill them by editing this page.
GLP-1 receptor agonist
Lixisenatide
Lixisenatide is a short-acting once-daily injectable GLP-1 receptor agonist approved for type 2 diabetes mellitus. It was approved by the FDA in July 2016 under the brand name Adlyxin (and as Lyxumia in the European Union), and was withdrawn from the United States market in 2023 by its manufacturer Sanofi, citing insufficient demand; it remains available in other markets. Pharmacologically it is most similar to exenatide, with which it shares the short-acting prandial-glucose-suppressing profile, in contrast with the long-acting once-weekly semaglutide and dulaglutide.
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Classes
GLP-1 receptor agonist
Pharmacy
Pharmacology